Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide

Chest

Volumn 131, Issue 5, 2007, Pages 1572-1574

  Thornburg, Aaron ^a   Abonour, Rafat ^a   Smith, Patricia ^a   Knox, Kenneth ^a   Twigg III, Homer L ^a  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Drug induced lung disease; Lenalidomide; Pneumonitis

Indexed keywords

AZITHROMYCIN; BORTEZOMIB; CEFALEXIN; CEFTAZIDIME; CYCLOPHOSPHAMIDE; DEXAMETHASONE; LENALIDOMIDE; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ADULT; ALLERGIC PNEUMONITIS; ARTICLE; ATELECTASIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BIOPSY; CASE REPORT; DISEASE COURSE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; HUMAN; HUMAN TISSUE; HYPOXIA; LIP DISEASE; LIP TINGLING; LUNG ALVEOLITIS; LUNG INFILTRATE; LYMPHOCYTIC ALVEOLITIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PARESTHESIA; PNEUMONIA; PRIORITY JOURNAL; RECURRENT DISEASE; THORAX RADIOGRAPHY;

EID: 34248587893     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.06-1734     Document Type: Article

References (14)

1. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352:549-557
2. Kyle RA, Vincent Rajkumar S. Treatment of multiple myeloma: an emphasis on new developments. Ann Med 2006; 38:111-115
3. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 1999; 163:380-386
4. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98:210-216
5. Morgan GJ, Krishnan B, Jenner M, et al. Advances in oral therapy for multiple myeloma. Lancet Oncol 2006; 7:316-325
6. Smith PA, Kohli LM, Wood KL, et al. Cytometric analysis of BAL T cells labeled with a standardized antibody cocktail correlates with immunohistochemical staining. Cytometry B Clin Cytom 2006; 70:170-178
7. Ozkan M, Dweik RA, Ahmad M. Drug-induced lung disease. Cleve Clin J Med 2001; 68:782-785, 789-795
8. Baughman RP, Judson MA, Teirstein AS, et al. Thalidomide for chronic sarcoidosis. Chest 2002; 122:227-232
9. Behrens RJ, Gulley JL, Dahut WL. Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide. Am J Ther 2003; 10:228-232
10. Carrion Valero F. Lung toxicity due to thalidomide [letter]. Arch Bronconeumol 2003; 39:286
11. Onozawa M, Hashino S, Sogabe S, et al. Side effects and good effects from new chemotherapeutic agents: case 2; Thalidomide-induced interstitial pneumonitis. J Clin Oncol 2005; 23:2425-2426
12. Costabel U, Uzaslan E, Guzman J. Bronchoalveolar lavage in drug-induced lung disease. Clin Chest Med 2004; 25:25-35
13. Miyakoshi S, Kami M, Yuji K, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006; 107:3492-3494
14. Usui Y, Aida H, Kimula Y, et al. A case of cyclophosphamide-induced interstitial pneumonitis diagnosed by bronchoalveolar lavage. Respiration 1992; 59:125-128